Ser712
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.6.0.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser712  -  PDGFRB (human)

Site Information
sDkRRPPsAELysNA   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 23130549

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, triple negative ( 2 ) , gastric cancer ( 1 ) , gastric carcinoma ( 1 ) , neuroblastoma ( 3 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
PKG2 (human) ( 1 )
Treatments:
8pCPT-cGMP ( 1 )

Downstream Regulation
Effects of modification on PDGFRB:
enzymatic activity, inhibited ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 )

References 

1

Wang Y, et al. (2018) PKG II inhibits PDGF-BB triggered biological activities by phosphorylating PDGFRβ in gastric cancer cells. Cell Biol Int
29935031   Curated Info

2

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

3

Guo A (2010) CST Curation Set: 10551; Year: 2010; Biosample/Treatment: cell line, SKNBE(2)/NGF; Disease: neuroblastoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info